Altered mitochondrial DNA copy number in cervical exfoliated cells among high‑risk HPV‑positive and HPV‑negative women.
cervical samples
copy number
high-risk HPV
mitochondria DNA
Journal
Experimental and therapeutic medicine
ISSN: 1792-1015
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
04
04
2023
accepted:
16
08
2023
medline:
19
10
2023
pubmed:
19
10
2023
entrez:
19
10
2023
Statut:
epublish
Résumé
The majority of cervical cancer cases are due to human papillomavirus (HPV) infection. However, certain cases of cervical cancer are not caused by HPV. Recent studies have shown a link between altered mitochondrial DNA (mtDNA) copy number, an indicative measure of mitochondrial dysfunction, and cervical cancer in women who test positive for HPV. However, the role of the mtDNA copy number in HPV-negative cervical cancer has remained elusive. In the present study, the mtDNA copy number was determined using quantitative PCR as the ratio between mtDNA and nuclear DNA in 287 ThinPrep cervical samples, including 143 cases with cervical abnormalities and 144 control subjects with high-risk (hr)-HPV positive or HPV-negative status. In an overall analysis of cases categorized based on the cytology diagnosis into squamous cervical carcinoma/high-grade squamous intraepithelial lesions (SCC/HSIL), low-grade squamous intraepithelial lesions (LSIL) and normal controls, the mtDNA copy number was significantly higher in all cases compared to the controls and a higher mtDNA copy number was observed in SCC/HSIL compared to LSIL cases. In the stratification analyses based on hr-HPV positive and HPV-negative status, an increased mtDNA copy number was observed in the cases compared with the controls regardless of their HPV status (P<0.05). When cases with cervical abnormalities were categorized based on histological diagnosis into cervical intraepithelial neoplasia (CIN)2/CIN3 and CIN1, an overall analysis indicated an increased mtDNA copy number in CIN2/CIN3 compared to CIN1 (P=0.01). Stratification analyses of these cases based on HPV status revealed a higher mtDNA copy number in CIN2/CIN3 compared to CIN1 regardless of HPV infection (P<0.05). These results showed that an elevated mtDNA copy number in subjects with cervical abnormalities was not influenced by the HPV status and suggested the possibility of its role in the progression of cervical cancer. The increased mtDNA copy number may be an adaptive response mechanism to compensate for mtDNA oxidative stress and energy deficiency, possibly induced by HPV infection and other environmental exposures.
Identifiants
pubmed: 37854504
doi: 10.3892/etm.2023.12220
pii: ETM-26-5-12220
pmc: PMC10580246
doi:
Types de publication
Journal Article
Langues
eng
Pagination
521Informations de copyright
Copyright © 2023, Spandidos Publications.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Int J Cancer. 1980 May 15;25(5):605-9
pubmed: 6246010
J Med Virol. 2011 Mar;83(3):453-60
pubmed: 21264866
CMAJ. 2022 May 2;194(17):E613-E615
pubmed: 35500920
Mitochondrion. 2014 May;16:73-82
pubmed: 23851045
Sex Med Rev. 2020 Jan;8(1):28-37
pubmed: 31791846
Lancet. 2007 Sep 8;370(9590):890-907
pubmed: 17826171
Gynecol Oncol. 2013 Apr;129(1):193-8
pubmed: 23319113
Diagnostics (Basel). 2021 May 26;11(6):
pubmed: 34073478
Clin Chim Acta. 2010 Apr 2;411(7-8):592-6
pubmed: 20114042
Biochem Biophys Rep. 2021 Feb 03;26:100931
pubmed: 33644420
Prz Menopauzalny. 2014 May;13(2):136-44
pubmed: 26327844
Biochem J. 2000 Jun 1;348 Pt 2:425-32
pubmed: 10816438
Sci Rep. 2016 Oct 24;6:35859
pubmed: 27775013
Gynecol Oncol. 2011 Jan;120(1):89-93
pubmed: 20950847
Carcinogenesis. 2015 Nov;36(11):1397-406
pubmed: 26354779
J Virol. 2014 Jun;88(12):6751-61
pubmed: 24696478
Int J Gynecol Cancer. 2022 Jan;32(1):1-7
pubmed: 34725203
Chin J Cancer Res. 2020 Dec 31;32(6):720-728
pubmed: 33446995
Cancer Cytopathol. 2015 May;123(5):271-81
pubmed: 25931431
Neuromolecular Med. 2020 Jun;22(2):304-313
pubmed: 31902116
Int J Cancer. 2014 Jul 15;135(2):453-66
pubmed: 24338632
Int J Cancer. 2012 Nov 15;131(10):2349-59
pubmed: 22323075
Papillomavirus Res. 2017 Dec;4:85-89
pubmed: 29179875
Cancer Cytopathol. 2015 May;123(5):282-8
pubmed: 25864682
Gulf J Oncolog. 2019 Sep;1(31):7-13
pubmed: 31591985
Geburtshilfe Frauenheilkd. 2021 Oct;81(10):1145-1153
pubmed: 34629493
Sci Rep. 2016 Nov 18;6:37404
pubmed: 27857175
Eur J Public Health. 2020 Oct 1;30(5):1026-1027
pubmed: 31764976
BMC Womens Health. 2020 Jul 2;20(1):139
pubmed: 32615963
PLoS Med. 2017 Jun 27;14(6):e1002325
pubmed: 28654640
Neurobiol Aging. 2016 Feb;38:216.e7-216.e10
pubmed: 26639155
Int J Cancer. 2019 Jan 1;144(1):160-168
pubmed: 30098013
Nat Rev Cancer. 2007 Jan;7(1):11-22
pubmed: 17186016
J Genet Genomics. 2009 Mar;36(3):125-31
pubmed: 19302968
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Nat Rev Cancer. 2002 May;2(5):342-50
pubmed: 12044010
Oncol Rev. 2019 Apr 16;13(1):409
pubmed: 31044027
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Mitochondrion. 2011 Jul;11(4):559-63
pubmed: 21385627
PLoS One. 2022 Jun 29;17(6):e0270714
pubmed: 35767552
Int J Biochem Cell Biol. 2005 Apr;37(4):822-34
pubmed: 15694841
BMC Med. 2019 Dec 11;17(1):228
pubmed: 31829241
JAMA. 2018 Aug 21;320(7):674-686
pubmed: 30140884
Br J Cancer. 2003 Jan 13;88(1):63-73
pubmed: 12556961
Elife. 2016 Feb 22;5:
pubmed: 26901439
Int J Mol Med. 2022 Aug;50(2):
pubmed: 35713211
Cell Death Dis. 2015 Apr 02;6:e1710
pubmed: 25837486
J Autoimmun. 2019 Jan;96:142-146
pubmed: 30327147
J Clin Pathol. 1982 Jan;35(1):1-13
pubmed: 7037858
FEBS Lett. 2021 Apr;595(8):976-1002
pubmed: 33314045